NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $156.86 -2.53 (-1.59%) As of 08/13/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock About SPDR S&P Biotech ETF (NYSEARCA:XBI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$156.55▼$160.6750-Day Range$128.43▼$164.2852-Week Range$88.18▼$165.71Volume7.52 million shsAverage Volume9.18 million shsMarket Capitalization$10.24 billionAssets Under Management$10.77 billionDividend Yield0.36%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF Overview SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. Read More SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.55%0.57%0.51%0.53%Other Expenses0.00%0.52%0.53%0.60%0.54%Total Expense0.35%0.76%0.75%0.75%0.73%Fee Waiver0.00%-0.85%-0.67%-0.77%-0.68%Net Expense0.35%0.58%0.63%0.57%0.60% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XBI ETF News HeadlinesiShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?August 8, 2026 | fool.comThese New Drugs Could Fuel Fresh Highs for Biotech and Pharma StocksAugust 7, 2026 | barrons.comIran War: What Happened at 1:11 P.M. Outside D.C.?A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 trillion dollar financial story unfolding behind the Iran conflict. Addison Wiggin, founder of the Grey Swan Investment Fraternity, investigated the claims himself and found enough corroboration to bring the story forward. The full account follows the money behind the headlines and shows why the Iran situation may look very different than reported.August 14 at 1:00 AM | Banyan Hill Publishing (Ad)ETF Showdown: XBI vs PBE, Which Biotech Fund Wins?July 24, 2026 | 247wallst.comBiotech remains compelling even after major comeback. Here’s what investors sayJuly 22, 2026 | cnbc.comBuying Biotech's Policy Discount With XBI And IBB: Most 'Feared' Nation Policy, Less-Than-Feared DamageJuly 21, 2026 | seekingalpha.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $121.93 at the beginning of 2026. Since then, XBI shares have increased by 28.6% and is now trading at $156.86. Who are SPDR S&P Biotech ETF's major shareholders? Top institutional investors of SPDR S&P Biotech ETF include Annex Advisory Services LLC (0.37%), Polymer Capital Management HK LTD (0.16%), S&CO Inc. (0.14%) and Crescent Grove Advisors LLC (0.10%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotechnology Select Industry Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings165 Fund Statistics Assets Under Management$10.77 billion Average Daily Volume$8.04 million Discount/Premium0.05% Administrator, Advisor and Custodian AdministratorState Street Global Advisors Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume14,338 Put Options6,702 Call Options7,636 Short Interest78,847,922 shs Miscellaneous Outstanding Shares65,300,000Beta0.83 Creation Unit50,000 Creation Fee$250.00 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report Top 10 XBI HoldingsApogee Therapeutics (NASDAQ:APGE)Holding Weight: 1.65%Oruka Therapeutics (NASDAQ:ORKA)Holding Weight: 1.53%Dianthus Therapeutics (NASDAQ:DNTH)Holding Weight: 1.42%Erasca (NASDAQ:ERAS)Holding Weight: 1.38%Twist Bioscience (NASDAQ:TWST)Holding Weight: 1.37%Kymera Therapeutics (NASDAQ:KYMR)Holding Weight: 1.34%Spyre Therapeutics (NASDAQ:SYRE)Holding Weight: 1.33%CG Oncology (NASDAQ:CGON)Holding Weight: 1.32%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 1.32%Protagonist Therapeutics (NASDAQ:PTGX)Holding Weight: 1.31%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHow the JPMorgan $8,000 Gold Call Exposed the Biggest Mistake in Most Retirement AccountsJPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
